/

Empresas

Ke

No verificado

Keymed

Sobre qué escribimos

BancaBiologíaEmpresasFarmacéuticaSanidad

4 Comunicados de prensa

Ver todos los comunicados de prensa

23/12/2024

Farmacéutica

Sanidad

Biología

Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis

Fuente

Editor

1.00

0

12/09/2024

Farmacéutica

Sanidad

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

Fuente

Editor

1.00

0

28/08/2024

Farmacéutica

Sanidad

Empresas

Biología

Keymed Biosciences Announces Interim Results for First Half of 2024

Fuente

Editor

1.00

0

20/06/2024

Farmacéutica

Sanidad

Biología

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0